Literature DB >> 9811341

Leukocyte-suppressing influences of interleukin (IL)-10 in cardiac allografts: insights from IL-10 knockout mice.

A Räisänen-Sokolowski1, T Glysing-Jensen, M E Russell.   

Abstract

To investigate the role of interleukin (IL)-10 in late graft outcomes, we compared BALB/c donor hearts transplanted into immunosuppressed wild-type or IL-10 gene-deficient (-/-) C57BL recipients (n = 49) at 50 +/- 5 days. There was prominent leukocyte infiltration and parenchymal destruction with more severe vascular occlusion in grafts from IL-10 -/- recipients. An occlusive CD45+ arteritis with medial necrosis occurred with IL-10 deficiency instead of the a-smooth muscle actin-rich arteriosclerosis seen in wild-type recipients. Increased interferon (IFN)-gamma as well as Mac-1, inducible nitric oxide synthase, and allograft inflammatory factor-1 (but not CD3 and IL-4) transcript levels were seen in allografts from IL-10 -/- recipients as assessed by 32p reverse transcription polymerase chain reaction. We then evaluated the contribution of IFN-gamma-mediated responses by neutralizing IFN-gamma. Anti-IFN-gamma monoclonal antibody (MAb) treatment of IL-10 -/- recipients did not improve graft survival, parenchymal rejection, or occlusive arteritis, indicating that these processes are IFN-gamma independent. However, medial smooth muscle cell loss in IL-10 -/- recipients was attenuated by anti-IFN-gamma MAb. Hence, in this transplant model, IL-10 suppresses T cell and macrophage responses in the parenchyma and vasculature and confers a protective effect against late rejection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811341      PMCID: PMC1853400          DOI: 10.1016/S0002-9440(10)65737-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha.

Authors:  R T Gazzinelli; M Wysocka; S Hieny; T Scharton-Kersten; A Cheever; R Kühn; W Müller; G Trinchieri; A Sher
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

2.  Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques.

Authors:  M R Bennett; G I Evan; S M Schwartz
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

Review 3.  IL-10 immunosuppression in transplantation.

Authors:  J S Bromberg
Journal:  Curr Opin Immunol       Date:  1995-10       Impact factor: 7.486

4.  Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice.

Authors:  R P Lowry; B Konieczny; D Alexander; C Larsen; T Pearson; S Smith; S Narula
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

5.  Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis.

Authors:  M E Russell; A F Wallace; L R Wyner; J B Newell; M J Karnovsky
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

6.  Effect of interleukin-4 and interleukin-10 on leucocyte migration and nitric oxide production in the mouse.

Authors:  M Perretti; C Szabó; C Thiemermann
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

7.  Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta.

Authors:  Y J Geng; Q Wu; M Muszynski; G K Hansson; P Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-01       Impact factor: 8.311

8.  The role of IL-10 in human B cell activation, proliferation, and differentiation.

Authors:  K Itoh; S Hirohata
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

9.  Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis.

Authors:  M E Russell; W W Hancock; E Akalin; A F Wallace; T Glysing-Jensen; T A Willett; M H Sayegh
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

10.  Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses.

Authors:  D J Berg; M W Leach; R Kühn; K Rajewsky; W Müller; N J Davidson; D Rennick
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

Review 2.  Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation.

Authors:  S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2013-07-02       Impact factor: 3.119

3.  Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-dependent pathway.

Authors:  Sifeng Chen; Matthias H Kapturczak; Clive Wasserfall; Olena Y Glushakova; Martha Campbell-Thompson; Jessy S Deshane; Reny Joseph; Pedro E Cruz; William W Hauswirth; Kirsten M Madsen; Byron P Croker; Kenneth I Berns; Mark A Atkinson; Terence R Flotte; C Craig Tisher; Anupam Agarwal
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-06       Impact factor: 11.205

4.  IL-10 for cardiac autophagy modulation: New direction in the pursuit of perfection.

Authors:  Anweshan Samanta; Buddhadeb Dawn
Journal:  J Mol Cell Cardiol       Date:  2016-01-07       Impact factor: 5.000

Review 5.  Cardiac allograft vasculopathy: the Achilles' heel of long-term survival after cardiac transplantation.

Authors:  Amandeep Dhaliwal; Vinay Thohan
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.